Cresset Asset Management’s C4 Therapeutics CCCC Stock Holding History

Cresset Asset Management’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$65.8K	Hold	25,000	–	–	﹤0.01%	1568
2025 Q4	$47.8K	Hold	25,000	–	–	﹤0.01%	1615
2025 Q3	$55.5K	Hold	25,000	–	–	﹤0.01%	1526
2025 Q2	$35.8K	Sell	25,000 -978	-4%	-$1.42K	﹤0.01%	1396
2025 Q1	$41.6K	Buy	25,978 +978	+4%	+$2.92K	﹤0.01%	1664
2024 Q4	$90K	Hold	25,000	–	–	﹤0.01%	1633
2024 Q3	$143K	Hold	25,000	–	–	﹤0.01%	2009
2024 Q2	$116K	Buy	+25,000	New	+$149K	﹤0.01%	1940
2024 Q1	–	Sell	-25,000	Closed	-$141K	–	1917
2023 Q4	$141K	Hold	25,000	–	–	﹤0.01%	1731
2023 Q3	$46.5K	Buy	25,000 +5,000	+25%	+$15.3K	﹤0.01%	1751
2023 Q2	$55K	Buy	20,000 +8,719	+77%	+$28K	﹤0.01%	1842
2023 Q1	$35.4K	Sell	11,281 -34,600	-75%	-$204K	﹤0.01%	796
2022 Q4	$268K	Hold	45,881	–	–	﹤0.01%	563
2022 Q3	$402K	Sell	45,881 -5,536	-11%	-$57.5K	0.01%	574
2022 Q2	$387K	Buy	51,417 +6,036	+13%	+$53.1K	﹤0.01%	636
2022 Q1	$1.1M	Buy	45,381 +2,000	+5%	+$48.6K	0.01%	383
2021 Q4	$1.4M	Buy	+43,381	New	+$1.72M	0.01%	364

Other funds holding CCCC

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cresset Asset Management's CCCC Position: Q1 2026 in Review

Cresset Asset Management held its C4 Therapeutics (CCCC) position steady in Q1 2026 at 25,000 shares worth $65.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1568.

Cresset Asset Management first reported a position in CCCC in Q4 2021 and has held it in 17 quarters since. The position peaked at $1.4M in Q4 2021. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

Cresset Asset Management held 25,000 shares of C4 Therapeutics worth $65.8K as of Q1 2026.
Cresset Asset Management left its C4 Therapeutics share count unchanged in Q1 2026.
C4 Therapeutics made up ﹤0.01% of Cresset Asset Management's portfolio in Q1 2026, its #1568 holding.
Cresset Asset Management first reported a position in C4 Therapeutics in Q4 2021 and has held it in 17 quarters since.
Cresset Asset Management's C4 Therapeutics position peaked at $1.4M in Q4 2021.
123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Cresset Asset Management's 13F filing for Q1 2026, filed 15 May 2026.